Combination of bevacizumab and irradiation on uveal melanoma: An in vitro and in vivo preclinical study

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 59-65

  Sudaka, Anne ^a   Susini, Antoine ^b   Lo Nigro, Cristiana ^c   Fischel, Jean Louis ^a   Toussan, Nicolas ^a   Formento, Patricia ^a   Tonissi, Federica ^c   Lattanzio, Laura ^c   Russi, Elvio ^c   Etienne Grimaldi, Marie Christine ^a   Merlano, Marco ^c   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b Ophthalmology Department   (France)

^c S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Irradiation; OCM 1; Uveal melanoma

Indexed keywords

BEVACIZUMAB; KI 67 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN OCM 1; CHEMORADIOTHERAPY; COCULTURE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN SECRETION; RADIATION RESPONSE; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; UVEA MELANOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA; MICE; MICE, NUDE; TUMOR BURDEN; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873089738     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9834-6     Document Type: Article

References (30)

1. Gragoudas ES, Goietin M, Verhey L, Munzenreider J, Suit HD, Koehler A (1980) Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophtalmology 87:571-581
2. Desjardins L, Levy C, d'Hermies F, Frau E, Schlienger P, Habrand JL, Mammar H, Schwartz L, Mazal A, Delacroix S, Nauraye C, Ferrand R, Asselain B (1997) Résultats préliminaires de la protonthérapie du mélanome de la choroïde au centre de protonthérapie d'Orsay (CPO): les 464 premiers cas. Cancer Radiother 1:222-226
3. Courdi A, Caujolle JP, Grange JD, Diallo-Rosier L, Sahel J, Bacin F, Zur C, Gastaud P, Iborra-Brassart N, Hérault J, Chauvel P (1999) Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys 45:5-11
4. Char DH, Quivey JM, Castro JR, Kroll PT (1993) Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophtalmology 100:1547-1554
5. Egan KM, Gragoudas ES, Seddon JM, Glynn RJ, Munzenreider JE, Goitein M, Verhey L, Urie M, Koehler A (1989) The risk of enucleation after proton beam irradiation of uveal melanoma. Ophtalmology 96:1377-1382
6. Egan KM, Ryan LM, Gragoudas ES (1998) Survival implications of enucleation after definitive radiotherapy for choroïdal melanoma: an example of regression on time-dependent covariates. Arch Ophthalmol 116:366-370
7. Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG (2000) Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophtalmol 84:750-756
8. Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA (2002) Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophtalmol 86:448-452
9. Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, Jager MJ (2006) Vascular endothelial growth factor in eyes with uveal melanoma. Arch Ophtalmol 124:1428-1434
10. Rosenblatt MI, Azar DT (2006) Antiangiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol 21:151-160
11. Triozzi PL, Eng C, Singh AD (2008) Targeted therapy for uveal melanoma. Cancer Treat Rev 34:247-258
12. Spagnolo F, Caltabiano G, Queirolo P (2012) Uveal melanoma. Cancer Treat Rev (in press)
13. O'Reilly M (2006) Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16:45-50
14. Kan-Mitchell J, Mitchell MS, Rao N, Ligett PE (1989) Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 30:829-834
15. Carmichael J, De Graff W, Gazdar AF, Mumma JO, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensibility testing. Cancer Res 47:936-940
16. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495-511
17. Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134:51-57
18. Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J (2009) Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 93:305-309
19. el Filali M, van der Velden PA, Luyten GP, Jager MJ (2012) Anti-angiogenic therapy in uveal melanoma. Dev Ophthalmol 49:117-136
20. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835-842
21. Nieder C, Wiedenmann N, Andraschke M, Molls N (2006) Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32:348-364
22. Finger PT (2008) Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 70:974-977
23. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989
24. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395-3402
25. Yang H, Jager MJ, Grossniklaus HE (2010) Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 51:2835-2842
26. Lefèvre G, Babchia N, Calipel A, Mouriaux F, Faussat AM, Mrzyk S, Mascarelli F (2009) Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci 50:1047-1057
27. Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135:807-810
28. Adams KS, Abramson DH, Ellsworth RM, Haik BG, Bedford M, Packer S, Seddon J, Albert D, Polivogianis L (1988) Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol 72:494-497
29. Depotter P, Shields CL, Shields JA, Cater JR, Tardio DJ (1994) Impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival. Br J Ophthalmol 78:109-114
30. Augsburger JJ, Schneider S, Freire J, Brady LW (1999) Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroïdal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 237:555-559